
Robert F. Kennedy Jr. Vows Overhaul of U.S. Vaccine Injury Compensation Program
Jul 29, 2025 02:00 am UTC| Governance Health Politics
U.S. Health Secretary Robert F. Kennedy Jr. announced plans to reform the National Vaccine Injury Compensation Program (VICP), pledging to address what he calls inefficiencies and corruption within the system. Kennedy, a...

FDA Approves PTC Therapeutics’ Sephience for Rare Genetic Disorder PKU
Jul 29, 2025 00:54 am UTC| Governance Health
The U.S. Food and Drug Administration (FDA) has approved PTC Therapeutics (NASDAQ:PTCT) oral drug Sephience to treat phenylketonuria (PKU), a rare inherited metabolic disorder affecting the bodys ability to break down the...

FDA Probes Death of 8-Year-Old Linked to Sarepta’s Elevidys Gene Therapy
Jul 26, 2025 00:58 am UTC| Business Governance Health
The U.S. Food and Drug Administration (FDA) is investigating the death of an eight-year-old boy who received Sarepta Therapeutics (NASDAQ: SRPT) gene therapy, Elevidys, for Duchenne muscular dystrophy (DMD). The incident...

Abivax Shares Soar 475% on Positive Phase 3 Ulcerative Colitis Trial Results
Jul 23, 2025 02:13 am UTC| Business Health
Abivax SA (NASDAQ:ABVX) shares surged in post-market trading Tuesday after the French biotech firm announced successful Phase 3 trial results for its ulcerative colitis treatment, obefazimod. The oral therapy met its...

Sanofi to Acquire UK Vaccine Firm Vicebio in $1.6B Deal to Boost Respiratory Portfolio
Jul 22, 2025 09:13 am UTC| Business Health
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced its acquisition of UK-based biotech firm Vicebio in a deal valued at up to $1.6 billion, aiming to expand its pipeline of respiratory vaccines. The agreement...

AstraZeneca Commits $50B to U.S. Expansion Amid Trump Tariff Push
Jul 22, 2025 01:18 am UTC| Health Business
AstraZeneca (NASDAQ: AZN) has unveiled plans to invest $50 billion in U.S. manufacturing and RD infrastructure by 2030, marking one of the largest expansions in the pharmaceutical industry. The move responds to renewed...

FDA Panel Rejects Otsuka’s PTSD Drug Combo with Zoloft
Jul 19, 2025 02:42 am UTC| Governance Health
A U.S. Food and Drug Administration (FDA) advisory panel has voted overwhelmingly against the approval of Otsuka Pharmaceuticals antipsychotic drug, brexpiprazole (Rexulti), in combination with Viatris antidepressant...